Evidence map›Paper›PMID 31515650›Full record

ArticleCytotechnology2019

Real-time transfer of lentiviral particles by producer cells using an engineered coculture system.

Lauren M Timmins, Riya S Patel, Matthew S Teryek, Biju Parekkadan

Abstract read
In one paragraph

Article in Cytotechnology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Lauren M TimminsDepartment of Biomedical Engineering, Rutgers University, Piscataway, NJ, 08902, USA.
Riya S PatelDepartment of Biomedical Engineering, Rutgers University, Piscataway, NJ, 08902, USA.
Matthew S TeryekDepartment of Biomedical Engineering, Rutgers University, Piscataway, NJ, 08902, USA.
Biju ParekkadanDepartment of Biomedical Engineering, Rutgers University, Piscataway, NJ, 08902, USA. biju.parekkadan@rutgers.edu.ORCID http://orcid.org/0000-0002-3408-8085

Funding

Artificial, Humanized Stem Cell NichesR01EB012521 · NIBIB · RUTGERS, THE STATE UNIV OF N.J. · PI PAREKKADAN, BIJU · 2011 to 2021
$6.0M
A Functional genomics platform with integrated library cloning and molecular displayR01GM127353 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI LARMAN, HARRY BENJAMIN, PAREKKADAN, BIJU · 2018 to 2021
$1.4M
NIBIB NIH HHS R01 EB012521NIGMS NIH HHS R01 GM127353NIH HHS R01GM127353
6 · The paper itself

Abstract

Lentiviruses are quite effective gene delivery systems for stable production of genetically engineered human cells. However, prior to using lentivirus to deliver genetic materials to cells of interest, the normal course of production of these lentiviruses involves a lengthy collection, purification, preservation, and quantification process. In this report, we demonstrate the ability for producer HEK293T cells to simultaneously produce lentiviral particles and transduce (i.e., infect) target cells through a membrane-based coculture system in a continuous, real-time mode which negates the need for a separate viral collection and quantification process. The coculture system was evaluated for major design features such as variations in HEK293T seeding density, target cell type densities, as well as membrane porosities to identify key relationships between lentiviral particle production rate and infection kinetics for adherent and suspension cell types. As a proof-of-concept for the creation of an engineered cell immunotherapy, we describe the ability to engineer human T cells isolated from PBMCs under the control of this coculture system in under 6 days with a GFP construct. These studies suggest the capability to combine and more closely automate the transfection/transduction process in order to facilitate well-timed and cost-effective transduction of target cell types. These experiments provide novel insight into the forthcoming transition into improved manufacturing systems for viral production and subsequent cell engineering.

Indexed as

Engineered cell therapyLentivirus transductionScalable engineering systems

Identifiers

PMID31515650
PMCPMC6787137

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.